Dementia in Alzheimer's disease.
Should be taken with food.
Alzheimer Disease Initial 4 mg PO q12hr Maintenance Titrate to 8-12 mg PO q12hr; increase by 4 mg q12hr at no less than 4 week intervals Hepatic Impairment Moderate: (Child-Pugh score 7-9): Not to exceed 16 mg/day Severe: Not recommended
Not recommended
Renal Impairment Moderate: Not to exceed 16 mg/day Severe (CrCl <9 mL/min): Not recommended
Hypersensitivity; severe liver or kidney dysfunction; lactation; disorders of galactose metabolism; urinary retention or GI obstruction. Lactation.
Galantamine is a centrally-acting cholinesterase inhibitor, elevating acetylcholine in the cerebral cortex. Glutamine and serotonin levels may also be increase. It has nicotinic receptor agonist properties.
Mild-moderate hepatic impairment; supraventricular conduction abnormalities; asthma; COPD; pregnancy; peptic ulcers. May increase gastric acid production.
>10% Nausea (20-25%),Diarrhea (11-15%),Vomiting (11-15%) 1-10% Abdominal pain,Anorexia,Muscle cramp,Fatigue,Dizziness,Headache,Weight loss,Depression,Insomnia,UTI,Somnolence,Anemia,Syncope,Bradycardia Potentially Fatal: CV effects; convulsion; delirium; rectal haemorrhage; thrombocytopenia.
ncreased serum concentrations when used with drugs that inhibit CYP2D6 (e.g. quinidine, fluoxetine, fluvoxamine, and paroxetine) and CYP3A4 (e.g. ketoconazole and ritonavir). Cimetidine may increase the bioavailability of galantamine. Increased risk of gastric ulcer when used with NSAIDs. Potentially Fatal: Amiodarone, ?-blockers, diltiazem or verapamil; NSAIDs; digoxin.